COMPUGEN LTD (CGEN) Stock Fundamental Analysis
USA - NASDAQ:CGEN - IL0010852080 - Common Stock
1.545 USD
-0.09 (-5.79%)
Taking everything into account, CGEN scores 3 out of 10 in our fundamental rating. CGEN was compared to 534 industry peers in the Biotechnology industry. The financial health of CGEN is average, but there are quite some concerns on its profitability. CGEN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CGEN had negative earnings in the past year.
CGEN had a negative operating cash flow in the past year.
CGEN had negative earnings in each of the past 5 years.
CGEN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CGEN (-18.18%) is better than 77.90% of its industry peers.
CGEN's Return On Equity of -38.53% is fine compared to the rest of the industry. CGEN outperforms 72.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.18% | ||
| ROE | -38.53% | ||
| ROIC | N/A |
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 62.33%, CGEN is doing good in the industry, outperforming 79.03% of the companies in the same industry.
In the last couple of years the Gross Margin of CGEN has declined.
CGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGEN has more shares outstanding than it did 1 year ago.
CGEN has more shares outstanding than it did 5 years ago.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CGEN has an Altman-Z score of -4.52. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
CGEN has a Altman-Z score (-4.52) which is comparable to the rest of the industry.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.52 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 4.74 indicates that CGEN has no problem at all paying its short term obligations.
CGEN has a Current ratio (4.74) which is comparable to the rest of the industry.
CGEN has a Quick Ratio of 4.74. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN's Quick ratio of 4.74 is in line compared to the rest of the industry. CGEN outperforms 53.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.74 | ||
| Quick Ratio | 4.74 |
3. Growth
3.1 Past
CGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -120.00%.
Looking at the last year, CGEN shows a very negative growth in Revenue. The Revenue has decreased by -48.16% in the last year.
CGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.84% yearly.
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-48.16%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-81.24%
3.2 Future
The Earnings Per Share is expected to decrease by -18.07% on average over the next years. This is quite bad
Based on estimates for the next years, CGEN will show a decrease in Revenue. The Revenue will decrease by -1.00% on average per year.
EPS Next Y-114.63%
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%
EPS Next 5Y-18.07%
Revenue Next Year-85.35%
Revenue Next 2Y-32.81%
Revenue Next 3Y-11.31%
Revenue Next 5Y-1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CGEN's earnings are expected to decrease with -9.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%
5. Dividend
5.1 Amount
No dividends for CGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CGEN (11/7/2025, 11:22:11 AM)
1.545
-0.09 (-5.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.53%
Inst Owner Change-0.82%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap144.52M
Revenue(TTM)22.14M
Net Income(TTM)-19.36M
Analysts88
Price Target7.14 (362.14%)
Short Float %1.07%
Short Ratio2.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.63%
Min EPS beat(2)-42.6%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-86.89%
Min EPS beat(4)-193.59%
Max EPS beat(4)-20.66%
EPS beat(8)1
Avg EPS beat(8)-75.17%
EPS beat(12)4
Avg EPS beat(12)-42.88%
EPS beat(16)8
Avg EPS beat(16)-26.17%
Revenue beat(2)0
Avg Revenue beat(2)-54.18%
Min Revenue beat(2)-68.82%
Max Revenue beat(2)-39.54%
Revenue beat(4)0
Avg Revenue beat(4)-51.51%
Min Revenue beat(4)-91.73%
Max Revenue beat(4)-5.97%
Revenue beat(8)2
Avg Revenue beat(8)-17.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-64.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-56.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.88 | ||
| P/tB | 2.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.24
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.18% | ||
| ROE | -38.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.33% | ||
| FCFM | N/A |
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.39% | ||
| Cap/Sales | 1.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.74 | ||
| Quick Ratio | 4.74 | ||
| Altman-Z | -4.52 |
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)54.17%
Cap/Depr(5y)49.83%
Cap/Sales(3y)2.49%
Cap/Sales(5y)4.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-114.63%
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%
EPS Next 5Y-18.07%
Revenue 1Y (TTM)-48.16%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-81.24%
Revenue Next Year-85.35%
Revenue Next 2Y-32.81%
Revenue Next 3Y-11.31%
Revenue Next 5Y-1%
EBIT growth 1Y-335.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.3%
OCF growth 3YN/A
OCF growth 5YN/A
COMPUGEN LTD / CGEN FAQ
What is the fundamental rating for CGEN stock?
ChartMill assigns a fundamental rating of 3 / 10 to CGEN.
What is the valuation status of COMPUGEN LTD (CGEN) stock?
ChartMill assigns a valuation rating of 0 / 10 to COMPUGEN LTD (CGEN). This can be considered as Overvalued.
What is the profitability of CGEN stock?
COMPUGEN LTD (CGEN) has a profitability rating of 2 / 10.